Trader TV Watchlist - February 28, 2025

Friday February 28, 2025

Welcome to the TraderTV Live Morning Research Note. Here's what's making major moves in the market today.

TraderTV.LIVE™ features a daily live trading broadcast, professional education and an active community of more than 450,000 subscribers. Join us on YouTube every weekday from 8:30am to 4:30pm EST for the first and only professional trading show on YouTube Live!

Economic Events:

0830 - Core PCE Price Index (MoM): Expected 0.3%; Prior 0.2%
0830 - Core PCE Price Index (YoY): Expected 2.6%; Prior 2.8%
0830 - Personal Spending (MoM): Expected 0.2%; Prior 0.7%
0945 - Chicago PMI (Feb): Expected 40.5; Prior 39.5
1030 - Atlanta Fed GDPNow (Q1): Expected 2.3%; Prior 2.3%

Premarket Trading:

Trading Higher ($): BE, SOUN, STLA

Trading Lower ($): DUOL, NTAP, XPEV

Earnings Today:

Premarket: FUBO, RXRX, WULF

Post-market: LGVN, BTCM

CLICK CHART TO EXPAND

In The News

Crypto Stocks

-3.38%

Trading sharply lower with volume as a group after Bitcoin broke the 80k level in early morning trading. This follows a more than double digit drop for the cryptocurrency this week and is in spite of news the SEC has ruled Meme Coins are not securities

COIN, MSTR, MARA, RIOT, IBIT, ETHE, HUT, CLSK, HIVE

CLICK CHART TO EXPAND

NVIDIA Corp

-0.04%

Nvidia's stock tumbled over 8% yesterday, wiping out $273 billion in market value and bringing its market cap down to $2.94 trillion, leaving Apple as the only $3 trillion company. Despite posting strong earnings with revenue up 78% to $39.33 billion and a 93% surge in data center sales, investor concerns over export controls, tariffs, AI model efficiency, and slowing growth have weighed on the stock, which is down 10% in 2025. Nvidia expects a strong fiscal 2026, resolving production issues for its next-gen Blackwell chips. CEO Jensen Huang remains bullish on AI demand, noting next-gen models will require significantly more computing power, with cloud giants like Microsoft, Google, and Amazon continuing to drive Nvidia’s data center revenue.

NVDA

Dell Technologies Inc.

-3.64%

Dell Technologies shares are trading lower after reporting Q4 earnings of $2.68 per share, beating the $2.53 estimate, while revenue of $23.9 billion fell short of the $24.56 billion forecast but grew from $22.32 billion last year. The company expects its gross margin rate to decline by 100 basis points, citing a lower seasonal storage mix and a higher AI-optimized server mix. Additionally, the PC refresh cycle is expected to be stronger in the second half of the year.

CLICK CHART TO EXPAND

Meta Platforms Inc.

0.65%

Meta is doubling down on AI and wearable technology, unveiling plans for a standalone Meta AI app and launching its Aria Gen 2 smart glasses for research. The AI app, expected in Q2, aligns with CEO Mark Zuckerberg’s goal of making Meta the leader in AI, with monetization plans including subscriptions and paid recommendations. Meanwhile, the Aria Gen 2 glasses, an upgrade from the 2020 model, enhance Meta’s push into AI-driven wearables, featuring improved sensors and computing power for research in robotics and machine perception.

META

Tesla Inc

-0.32%

Shares of the EV maker are back on watch following another weak day as shares have now lost over 15% on the week and have seen it lose the 1 Trillion market cap threshold. In addition, according to reports by Forbes Cybertruck Inventories have been increasing due to lower than expected sales. Competitor Xiaomi has also cut the price of its luxury sedan by 35% highlighting further competition in China.

CLICK CHART TO EXPAND

Microsoft Corp.

-0.02%

OpenAI has launched a research preview of GPT-4.5, available first to developers and ChatGPT Pro users, with wider rollout planned for ChatGPT Plus. The model improves accuracy, user intent recognition, and emotional intelligence but won’t set new benchmark records, according to CEO Sam Altman. Microsoft, a key OpenAI backer, is offering GPT-4.5 through Azure AI Foundry. OpenAI is also reportedly in talks for a $40 billion funding round at a $340 billion valuation. The launch comes amid growing competition in AI, particularly from China’s DeepSeek, which contributed to a $600 billion single-day drop in Nvidia’s market cap last month..

MSFT

Chinese ADRs

-3.17%

U.S.-China trade tensions escalated with President Trump's announcement of additional 10% tariffs on Chinese imports, citing China’s role in the fentanyl trade. In response, China’s Ministry of Commerce strongly opposed the move, threatening retaliation, including higher tariffs on U.S. goods and tighter controls on critical minerals. While retaliation is expected to remain measured to avoid further economic strain, China’s stance has become more assertive. The U.S. is also set to review China’s trade deal compliance by April 1, potentially paving the way for further reciprocal tariffs. These developments continue to add uncertainty to global supply chains and could impact key sectors reliant on U.S.-China trade.

BABA, PDD, BIDU, JD, LI, XPEV, NIO, KWEB

Rocket Lab USA Inc

-14.83%

Rocket Lab (reported a Q4 loss of $0.10 per share, in line with estimates and unchanged from last year. Revenue reached $132.39 million, beating expectations of $130.58 million and growing 120.68% year-over-year. Shares are trading heavily lower as for Q1, the company forecasted revenue between $117 million and $123 million, below the $135.67 million estimate, and expects an adjusted EBITDA loss of $33 million to $35 million.

CLICK CHART TO EXPAND

Bioxcel Therapeutics Inc.

41.20%

BioXcel Therapeutics has regained compliance with Nasdaq’s minimum closing bid price requirement, following a notice from the Nasdaq Listing Qualifications Department. After previously being notified in September 2024 that its stock failed to meet the $1.00 per share bid price for 30 consecutive days, the company met the requirement by maintaining a minimum closing bid price of $1.00 for 12 consecutive trading days as of February 26, 2025. BioXcel, a biopharmaceutical firm using AI to develop neuroscience medicines, also focuses on immuno-oncology through its subsidiary, OnkosXcel Therapeutics

BTAI.